Trial Profile
A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms STEMALS-II
- 26 Nov 2020 Status changed from recruiting to discontinued.
- 01 Oct 2014 New trial record